Kymera Therapeutics Taps Sanofi Immunology Leader to Drive STAT6 Degrader Program
Event summary
- Kymera Therapeutics appoints Elizabeth Laws, Ph.D., as Senior Vice President to lead KT-621 development program.
- KT-621 is a first-in-class oral STAT6 degrader in Phase 2b trials for atopic dermatitis (AD) and asthma.
- Phase 2b AD trial enrollment complete; data expected by year-end 2026. Asthma trial ongoing with data due late 2027.
- Phase 3 trials in AD planned to initiate by mid-2027.
- Dr. Laws previously led global development of dupilumab at Sanofi.
The big picture
Kymera's appointment of a seasoned immunology leader underscores its push to establish targeted protein degradation as a viable therapeutic approach. The strategic move comes as the company races to differentiate KT-621 in a crowded inflammatory disease market, where oral therapies could gain preference over injectables. Success hinges on demonstrating superior efficacy and safety profiles in pivotal trials.
What we're watching
- Clinical Execution
- Whether KT-621 can deliver positive Phase 2b data in AD by year-end 2026 and sustain momentum into Phase 3.
- Pipeline Expansion
- The pace at which Kymera advances KT-621 across additional Type 2 inflammatory indications beyond AD and asthma.
- Commercial Strategy
- How Dr. Laws' Sanofi experience will shape KT-621's launch strategy, particularly in competing with established therapies like dupilumab.